LLY

1,018.6

+3.3%↑

JNJ

229.93

+0.53%↑

ABBV

213.62

+1.94%↑

UNH

389.29

-0.09%↓

AZN

184.71

+0.4%↑

LLY

1,018.6

+3.3%↑

JNJ

229.93

+0.53%↑

ABBV

213.62

+1.94%↑

UNH

389.29

-0.09%↓

AZN

184.71

+0.4%↑

LLY

1,018.6

+3.3%↑

JNJ

229.93

+0.53%↑

ABBV

213.62

+1.94%↑

UNH

389.29

-0.09%↓

AZN

184.71

+0.4%↑

LLY

1,018.6

+3.3%↑

JNJ

229.93

+0.53%↑

ABBV

213.62

+1.94%↑

UNH

389.29

-0.09%↓

AZN

184.71

+0.4%↑

LLY

1,018.6

+3.3%↑

JNJ

229.93

+0.53%↑

ABBV

213.62

+1.94%↑

UNH

389.29

-0.09%↓

AZN

184.71

+0.4%↑

Home・Aktien・Gossamer Bio Inc

Gossamer Bio Inc

Geschlossen

BrancheGesundheitswesen

0.2 17.65

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

0.19

Max

0.22

Schlüsselkennzahlen
By Trading Economics
Einkommen	574K -47M
Verkäufe	3.2M 17M
EPS	-0.2
Gewinnspanne	-275.223
Angestellte	161
EBITDA	947K -45M

Empfehlungen
By TipRanks
Empfehlungen	Neutral
12-Monats-Prognose	+2336.84% upside

Dividenden
By Dow Jones
Nächstes Ergebnis	3. Aug. 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	-34M 45M
Vorheriger Eröffnungskurs	-17.45
Vorheriger Schlusskurs	0.2

Nachrichtenstimmung

By Acuity

72%

28%

312 / 345 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Weak Bullish Evidence

1.06 / 1.23 Unterstützung & Widerstand

Gossamer Bio Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

19. Mai 2026, 20:36 UTC

Akquisitionen, Fusionen, Übernahmen

Analog Devices to Buy Empower Semiconductor for $1.5 Billion

19. Mai 2026, 23:47 UTC

Market Talk

Nikkei May Decline as Concerns About Energy, Material Costs Persists -- Market Talk

19. Mai 2026, 23:34 UTC

Market Talk

Gold Edges Higher on Possible Technical Recovery -- Market Talk

19. Mai 2026, 23:28 UTC

Market Talk

Ergebnisse

Global Forex and Fixed Income Roundup: Market Talk

19. Mai 2026, 23:28 UTC

Market Talk

Ergebnisse

F&P Healthcare's Outlook Key for Investors -- Market Talk

19. Mai 2026, 23:10 UTC

Market Talk

Global Equities Roundup: Market Talk

19. Mai 2026, 23:10 UTC

Market Talk

Kiwi Property's Dividend Growth Reliant on Several Factors -- Market Talk

19. Mai 2026, 22:02 UTC

Ergebnisse

ZTO Express (Cayman): Di Xu to Resign From Board

19. Mai 2026, 22:01 UTC

Ergebnisse

ZTO Express (Cayman) 1Q Adj EPS 43c >ZTO

19. Mai 2026, 22:01 UTC

Ergebnisse

ZTO Express (Cayman) 1Q EPS 39c >ZTO

19. Mai 2026, 22:00 UTC

Ergebnisse

ZTO Express (Cayman) 1Q Rev $1.93B >ZTO

19. Mai 2026, 21:37 UTC

Ergebnisse

Cracks Are Starting to Appear in the Chip Stock Rally -- Barrons.com

19. Mai 2026, 21:31 UTC

Akquisitionen, Fusionen, Übernahmen

How NextEra Can Fix Dominion's Strange AI Problem -- Barrons.com

19. Mai 2026, 21:01 UTC

Ergebnisse

Home Depot Beats Earnings Estimates as Shoppers Defy Inflation Fears. The Stock Advances. -- Barrons.com

19. Mai 2026, 20:58 UTC

Ergebnisse

These Stocks Are Today's Movers: CoreWeave, Nvidia, Home Depot, Akamai, Agilysys, Micron, and More -- Barrons.com

19. Mai 2026, 20:46 UTC

Heiße Aktien

Stocks to Watch Recap: ServiceNow, Home Depot, CoreWeave -- WSJ

19. Mai 2026, 20:43 UTC

Market Talk

Canada 30-Year Yield Hits Highest Level Since 2010 -- Market Talk

19. Mai 2026, 20:34 UTC

Ergebnisse

James Hardie Industries Sees FY27 Sales $5.25B-$5.41B >JHX

19. Mai 2026, 20:32 UTC

Ergebnisse

James Hardie Industries: Targeting Pro Forma Adjusted EBITDA Growth of 4% to 8% in FY27 >JHX

19. Mai 2026, 20:32 UTC

Ergebnisse

James Hardie Industries 4Q EPS 5c >JHX

19. Mai 2026, 20:32 UTC

Ergebnisse

James Hardie Industries 4Q Sales $1.4B >JHX

19. Mai 2026, 20:21 UTC

Akquisitionen, Fusionen, Übernahmen

Analog Devices to Buy Empower Semiconductor for $1.5B

19. Mai 2026, 20:18 UTC

Market Talk

Canada CPI Data Has Accounting Quirk Related to Travel Tours -- Market Talk

19. Mai 2026, 20:13 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

19. Mai 2026, 20:13 UTC

Market Talk

'Hard to Square' Canada Rate Hikes Expectations Given Mild Core -- Market Talk

19. Mai 2026, 20:03 UTC

Akquisitionen, Fusionen, Übernahmen

Analog Devices: Deal Further Advances Position as Strategic, System-Level Grid-To-Core Power Partner for Hyperscalers, AI Silicon Developers >ADI

19. Mai 2026, 20:03 UTC

Akquisitionen, Fusionen, Übernahmen

Analog Devices: Phillips Will Continue Leading IVR Technology Efforts as Part of ADI >ADI

19. Mai 2026, 20:02 UTC

Akquisitionen, Fusionen, Übernahmen

Analog Devices Will Acquire Empower in All-Cash Transaction for $1.5 B >ADI

19. Mai 2026, 20:02 UTC

Akquisitionen, Fusionen, Übernahmen

Analog Devices to Acquire Empower Semiconductor, Expanding Its Next-Generation High-Density Power Portfolio for the AI Era

19. Mai 2026, 19:23 UTC

Market Talk

Oil Futures Slip With Market Back on U.S.-Iran Deal Watch -- Market Talk

Peer-Vergleich

Kursveränderung

Gossamer Bio Inc Prognose

Kursziel

By TipRanks

2336.84% Vorteil

12-Monats-Prognose

Durchschnitt 4.63 USD 2336.84%

Hoch 15 USD

Tief 0.28 USD

Basierend auf 8 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Gossamer Bio Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Neutral

8 ratings

Buy

Halten

Sell

Basierend auf 8 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Gossamer Bio Inc – Dist abgegeben haben.

Technischer Score

By Trading Central

1.06 / 1.23Unterstützung & Widerstand

Bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

All events are bullish.

Stimmung

By Acuity

312 / 345 Ranking in Gesundheitswesen

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Gossamer Bio Inc

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.